Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00753896 · ClinicalTrials.gov registry record · Phase 3
Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 134
- Enrollment target
NCT00753896: Completed Phase 3 study, sponsored by AstraZeneca.
NCT00753896 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 134 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00753896, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 134 participants
- Enrollment target
Study Summary
This study will examine the safety of exenatide once weekly (2.0 mg) in approximately 134 patients receiving treatment with thiazolidinedione alone or thiazolidinedione in combination with metformin. Patients are expected to be treated with exenatide once weekly for at least 52 weeks.
Primary Outcome
Percentage of patients experiencing treatment-emergent adverse events over 52 weeks
Interventions
- DRUG exenatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2008-10 |
| Est. Completion | 2009-11 |
| Phase | Phase 3 |
What the finished NCT00753896 record still lists
NCT00753896 is an interventional study that assigns participants to a tested intervention. The registered 134 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 1 intervention - of which exenatide is the first listed.
NCT00753896 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00753896 about?
NCT00753896 is a clinical study titled "Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin". This study will examine the safety of exenatide once weekly (2.0 mg) in approximately 134 patients receiving treatment with thiazolidinedione alone or thiazolidinedione in combination with metformin. Patients are expected to be treated with exenatide once weekly for at least 52 weeks.
What is the current status of trial NCT00753896?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 134 participants. The study started on 2008-10. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00753896?
The interventions under investigation include: exenatide (DRUG).
Who is sponsoring clinical trial NCT00753896?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00753896's enrollment target sits among peer trials
134 1585th of 2000 higher than 413 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02469662 · 134 participants · NA
Clinical Outcomes Study of the Nexel Total Elbow
- NCT03110822 · 134 participants · Phase 1
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
- NCT04678648 · 134 participants · Phase 1
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
- NCT05264857 · 134 participants · NA
Decision Aid and Thyroid Nodules Management
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia